Molecular mechanism of the cell death induced by the histone deacetylase pan inhibitor LBH589 (panobinostat) in wilms tumor cells

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Yan Fang, Tao ^a   Zhi Heng, Li ^a   Li Xiao, Xu ^a   Fang, Fang ^a   Jun, Lu ^a   Gang, Li ^a   Lan, Cao ^a   Na Na, Wang ^a   Xiao Juan, Du ^b   Li Chao, Sun ^c   Wen Li, Zhao ^a   Pei Fang, Xiao ^a   He, Zhao ^a   Guang Hao, Su ^a   Yan Hong, Li ^a   Yi Ping, Li ^a   Yun Yun, Xu ^a   Hui Ting, Zhou ^a   Yi, Wu ^a   Mei Fang, Jin ^a   Lin, Liu ^a   Jian, Ni ^d   Shao Yan, Hu ^a   Xue Ming, Zhu ^a   Xing, Feng ^a   Jian, Wang ^a   Jian, Pan ^a   more..

^a CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b The 5th Hospital of Chinese PLA   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CYCLIN A2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HISTONE H1; HISTONE H3; HOE 33342; LIPOCORTIN 5; MESSENGER RNA; MYC PROTEIN; PANOBINOSTAT; PROPIDIUM IODIDE; RNA; HYDROXAMIC ACID; INDOLE DERIVATIVE; LONG UNTRANSLATED RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CLUSTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN CELL; MICROARRAY KIT; NEPHROBLASTOMA; NUCLEOSOME; NUDE MOUSE; RENAL CANCER CELL LINE; STAINING; TUMOR XENOGRAFT; TUNEL ASSAY; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MICE; MICE, NUDE; RNA, LONG NONCODING; WILMS TUMOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941360062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126566     Document Type: Article

References (55)

1. Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatric blood & cancer. 2008; 50(3):703-6. Epub 2006/12/13. doi: 10.1002/pbc.21099 PMID: 17154184.
2. Davenport KP, Blanco FC, Sandler AD. Pediatric malignancies: neuroblastoma, Wilm's tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma. Surg Clin North Am. 92(3):745-67, x. PMID: 22595719. doi: 10.1016/j.suc.2012.03.004
3. Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L, et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC cancer. 2012; 12:619. Epub 2012/12/27. doi: 10.1186/1471-2407-12-619 PMID: 23267699; PubMed Central PMCID: PMC3543843.
4. Bahari-Javan S, Maddalena A, Kerimoglu C, Wittnam J, Held T, Bahr M, et al. HDAC1 regulates fear extinction in mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012; 32(15):5062-73. Epub 2012/04/13. doi: 10.1523/JNEUROSCI.0079-12.2012 PMID: 22496552.
5. Bellucci L, Dalvai M, Kocanova S, Moutahir F, Bystricky K. Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PloS one. 2013; 8(1):e54102. Epub 2013/01/26. doi: 10.1371/journal. pone.0054102 PMID: 23349794; PubMed Central PMCID: PMC3548890.
6. Brilli LL, Swanhart LM, de Caestecker MP, Hukriede NA. HDAC inhibitors in kidney development and disease. Pediatr Nephrol. 2013; 28(10):1909-21. Epub 2012/10/12. doi: 10.1007/s00467-012-2320-8 PMID: 23052657; PubMed Central PMCID: PMC3751322.
7. Valente S, Mai A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and noncancer diseases: a patent review (2011-2013). Expert opinion on therapeutic patents. 2014; 24 (4):401-15. Epub 2014/01/09. doi: 10.1517/13543776.2014.877446 PMID: 24397271.
8. Ren J, Zhang J, Cai H, Li Y, Zhang Y, Zhang X, et al. HDAC as a therapeutic target for treatment of endometrial cancers. Current pharmaceutical design. 2014; 20(11):1847-56. Epub 2013/07/31. PMID: 23888962.
9. Li X, Zhang J, Xie Y, Jiang Y, Yingjie Z, Xu W. Progress of HDAC inhibitor panobinostat in the treatment of cancer. Current drug targets. 2014; 15(6):622-34. Epub 2014/03/07. PMID: 24597570.
10. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014. Epub 2014/08/15. PMID: 25115382.
11. Juengel E, Nowaz S, Makarevi J, Natsheh I, Werner I, Nelson K, et al. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Molecular cancer. 2014; 13:152. Epub 2014/06/18. doi: 10.1186/1476-4598-13-152 PMID: 24935000; PubMed Central PMCID: PMC4073177.
12. Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T. Histone deacetylase inhibitors in cancer therapy. A review. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2014; 158(2):161-9. Epub 2013/11/23. doi: 10.5507/bp.2013.085 PMID: 24263215.
13. Hsieh YJ, Hwu L, Chen YC, Ke CC, Chen FD, Wang HE, et al. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2014; 55(4):678-85. Epub 2014/03/19. doi: 10.2967/jnumed.113.126573 PMID: 24639460.
14. Scuto A, Kirschbaum M, Buettner R, Kujawski M, Cermak JM, Atadja P, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-kappaB/STAT3 complex to its promoter in malignant lymphoid cells. Cell death & disease. 2013; 4:e635. Epub 2013/05/18. doi: 10.1038/cddis.2013.159 PMID: 23681230; PubMed Central PMCID: PMC3674366.
15. Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(1):223-34. Epub 2006/01/07. doi: 10.1158/1078-0432.CCR-05-1225 PMID: 16397046.
16. Zhao Y, Yu D, Wu H, Liu H, Zhou H, Gu R, et al. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo. International journal of oncology. 2014; 44(2):451-8. Epub 2013/12/04. doi: 10.3892/ijo.2013.2193 PMID: 24297449.
17. Yan SF, You HJ, Xing TY, Zhang CG, Ding W. HDAC inhibitor sodium butyrate augments the MEF2C enhancement of Nampt expression under hypoxia. Current pharmaceutical design. 2014; 20 (11):1604-13. Epub 2013/07/31. PMID: 23888946.
18. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. The Journal of clinical investigation. 2014; 124(1):30-9. Epub 2014/01/03. doi: 10.1172/JCI69738 PMID: 24382387; PubMed Central PMCID: PMC3871231.
19. Wang LT, Liou JP, Li YH, Liu YM, Pan SL, Teng CM. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCdelta and Ecadherin. Oncotarget. 2014; 5(14):5651-62. Epub 2014/07/13. PMID: 25015091.
20. Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, et al. Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer research. 2013; 33(10):4475-81. Epub 2013/10/15. PMID: 24123018.
21. Shi B, Xu W. The development and potential clinical utility of biomarkers for HDAC inhibitors. Drug discoveries & therapeutics. 2013; 7(4):129-36. Epub 2013/09/28. PMID: 24071574.
22. Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, Filetti S, et al. Targeting histone deacetylase in thyroid cancer. Expert opinion on therapeutic targets. 2013; 17(2):179-93. Epub 2012/12/14. doi: 10. 1517/14728222.2013.740013 PMID: 23234477.
23. Mithraprabhu S, Khong T, Jones SS, Spencer A. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. British journal of haematology. 2013; 162(4):559-62. Epub 2013/05/23. doi: 10.1111/bjh.12388 PMID: 23692150.
24. Fortunati N, Marano F, Bandino A, Frairia R, Catalano MG, Boccuzzi G. The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. International journal of oncology. 2014; 44(3):700-8. Epub 2013/12/25. doi: 10.3892/ijo.2013.2218 PMID: 24366407.
25. Xu M, Hong M, Xie H. Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2013; 33(10):1409-15. Epub 2013/10/23. PMID: 24144737.
26. Xiao W, Graham PH, Hao J, Chang L, Ni J, Power CA, et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PloS one. 2013; 8(8):e74253. Epub 2013/08/31. doi: 10.1371/journal.pone.0074253 PMID: 23991216; PubMed Central PMCID: PMC3753304.
27. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma research. 2013. Epub 2013/08/22. doi: 10.1097/CMR. 0b013e328364c0ed PMID: 23963286.
28. Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PloS one. 2013; 8(9):e76662. Epub 2013/10/08. doi: 10.1371/journal.pone.0076662 PMID: 24098799; PubMed Central PMCID: PMC3786928.
29. Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, et al. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Molecular cancer. 2013; 12(1):114. Epub 2013/10/08. doi: 10.1186/1476-4598-12-114 PMID: 24093956; PubMed Central PMCID: PMC3853770.
30. Jeon YJ, Ko SM, Cho JH, Chae JI, Shim JH. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. International journal of molecular medicine. 2013; 32(4):860-6. Epub 2013/07/24. doi: 10.3892/ijmm.2013.1451 PMID: 23877235.
31. Ma YY, Lin H, Moh JS, Chen KD, Wang IW, Ou YC, et al. Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells. Taiwanese journal of obstetrics & gynecology. 2011; 50(2):165-71. Epub 2011/07/28. doi: 10.1016/j.tjog.2011.01.022 PMID: 21791302.
32. de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, et al. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013; 8(8):1091-4. Epub 2013/07/17. doi: 10.1097/JTO.0b013e318293d88c PMID: 23857399.
33. Darzynkiewicz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using TUNEL assay. Methods. 2008; 44(3):250-4. Epub 2008/03/04. doi: 10.1016/j.ymeth.2007.11.008 PMID: 18314056; PubMed Central PMCID: PMC2295206.
34. Yu G, Yao W, Wang J, Ma X, Xiao W, Li H, et al. LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray. PloS one. 2012; 7(8):e42377. Epub 2012/08/11. doi: 10.1371/journal. pone.0042377 PMID: 22879955; PubMed Central PMCID: PMC3412851.
35. Wegert J, Bausenwein S, Kneitz S, Roth S, Graf N, Geissinger E, et al. Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro. Molecular cancer. 2011; 10:136. Epub 2011/11/10. doi: 10.1186/1476-4598-10-136 PMID: 22067876; PubMed Central PMCID: PMC3239322.
36. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2005; 113(4):264-8. Epub 2005/05/04. doi: 10.1111/j.1600-0463.2005.apm-04.x PMID: 15865607.
37. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Annals of the New York Academy of Sciences. 2003; 983:220-31. Epub 2003/05/02. PMID: 12724227.
38. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer cell. 2004; 5(5):455-63. Epub 2004/05/18. PMID: 15144953.
39. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(6):1669-77. Epub 2008/03/19. doi: 10.1158/1078-0432. CCR-07-0990 PMID: 18347167.
40. Gotze S, Coersmeyer M, Muller O, Sievers S. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells. International journal of oncology. 2014. Epub 2014/07/23. doi: 10.3892/ijo.2014.2550 PMID: 25050608.
41. Chou CW, Wu MS, Huang WC, Chen CC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PloS one. 2011; 6(3):e18087. Epub 2011/04/06. doi: 10.1371/journal.pone. 0018087 PMID: 21464950; PubMed Central PMCID: PMC3064594.
42. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature reviews Drug discovery. 2006; 5(9):769-84. Epub 2006/09/07. doi: 10.1038/nrd2133 PMID: 16955068.
43. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncology reports. 2007; 18(4):769-74. Epub 2007/09/06. PMID: 17786334.
44. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(1):91-9. Epub 2009/01/02. doi: 10.1158/1078-0432.CCR-08-0684 PMID: 19118036.
45. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia & lymphoma. 2008; 49(3):502-7. Epub 2008/02/26. doi: 10.1080/10428190701817258 PMID: 18297527.
46. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2008; 19(5):964-9. Epub 2008/02/26. doi: 10.1093/annonc/mdn031 PMID: 18296419.
47. Scuto A, Kirschbaum M, Kowolik C, Kretzner L, Juhasz A, Atadja P, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Phacute lymphoblastic leukemia cells. Blood. 2008; 111(10):5093-100. Epub 2008/03/20. doi: 10.1182/blood-2007-10-117762 PMID: 18349321; PubMed Central PMCID: PMC2384136.
48. Chuang MJ, Wu ST, Tang SH, Lai XM, Lai HC, Hsu KH, et al. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PloS one. 2013; 8(9):e73401. Epub 2013/09/12. doi: 10.1371/journal.pone.0073401 PMID: 24023871; PubMed Central PMCID: PMC3762759.
49. Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013; 121(8):1296-303. Epub 2013/01/05. doi: 10.1182/blood-2012-06-439307 PMID: 23287861; PubMed Central PMCID: PMC3578951.
50. Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, et al. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(8):2230-9. Epub 2012/03/07. doi: 10.1158/1078-0432.CCR-11-1764 PMID: 22392915.
51. Xu M, Knox AJ, Michaelis KA, Kiseljak-Vassiliades K, Kleinschmidt-DeMasters BK, Lillehei KO, et al. Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity. Endocrinology. 2012; 153(7):2963-73. Epub 2012/05/09. doi: 10.1210/en.2011-2021 PMID: 22562171.
52. Bernal C, Aguayo F, Villarroel C, Vargas M, Diaz I, Ossandon FJ, et al. Reprimo as a potential biomarker for early detection in gastric cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(19):6264-9. Epub 2008/10/03. doi: 10.1158/1078-0432. CCR-07-4522 PMID: 18829507.
53. Beasley WD, Beynon J, Jenkins GJ, Parry JM. Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case-control disease association study. International journal of colorectal disease. 2008; 23(4):375-81. Epub 2008/01/17. doi: 10.1007/s00384-007-0435-3 PMID: 18197409.
54. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. The Journal of biological chemistry. 2000; 275 (30):22627-30. Epub 2000/08/10. doi: 10.1074/jbc.C000235200 PMID: 10930422.
55. Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H, Watanabe M. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. Molecular cancer research: MCR. 2013; 11(11):1362-74. Epub 2013/08/29. doi: 10.1158/1541-7786.MCR-13-0091 PMID: 23982217.